Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2013 / Jul / Pre-diabetic Profiling
Mass Spectrometry Omics Metabolomics Lipidomics Chromatography Liquid Chromatography Chromatography Gas Chromatography

Pre-diabetic Profiling

By Rich Whitworth 07/23/2013 1 min read

Share

The strength of the study lies in the breadth of metabolites that can be measured and compared between healthy individuals, pre-diabetic subjects, and confirmed type 2 diabetes mellitus patients. The group obtained a large amount of spectral data from these three cohorts and used multivariate analysis (OPLS-DA) to observe three distinct clusters, identifying further metabolites that were markedly different between them using the “variable importance in the projection” values.  But Ong is already looking to build on the findings. “One main limitation was the small number of pre-diabetic subjects (24 out of the total 111 serum samples assayed). We are extending this to a larger cohort and also want to look into the temporal changes of the disease biomarkers,” he explains.  Though Ong’s group has already studied metabolite profiles of other diseases, such as asthma and cancer, this is the first time that they have included a non-clinic-based, community component – and the findings were not entirely expected. “The extensive metabolite shifts among the pre-diabetic subjects was certainly a surprise,” he says (see Figure 1 & 2). “It suggests that subtle pathophysiological changes have already taken place in these subjects and that our integrated approach can be used for early detection of diabetes, which is of public significance.” Regarding insights into the disease mechanism, Ong says that, “Our overall findings suggest that metabolic interplay between a number of pathways is associated with the development of diabetes.”  RW

Samples are assayed in parallel using GC-MS and LC-MS.

Systems:

Agilent 6890 GC system equipped with a 7683 autosampler and HP-5MSI fused-silica capillary column. 

Agilent 1200 HPLC with an Agilent rapid resolution HT zorbax SB-C18 column (2.1 × 50 mm, 1.8µm).

Agilent 6410 Triple Quad mass spectrometer, managed by a MassHunter workstation.

Data Analysis: 

Spectral data were analyzed using orthogonal projection to latent structures discriminant analysis (OPLS-DA; program: SIMCA-P+ 11) to model predictors (variables/molecular ions) to responses (disease progression).

The prevalence of type 2 diabetes mellitus (T2DM) is on a rampant rise across the globe, making it a critical area of study for metabolomics and biomarker discovery. The bad news is that the disease results from a complex interplay of genetic, metabolic, and environmental factors, complicating analysis. The good news is that progress is being made. Last month, we covered the molecular signatures of diabetic wound healing (1). Here, Choon Nam Ong, director of the Environmental Research Institute at the National University of Singapore, describes his group’s recent research (2). 

“The aim of our diabetes metabolite study was to investigate the potential of a metabolomics approach for the early detection of T2DM, even before the occurrence of hyperglycemia,” Ong explains. His group’s metabolomic platform technology allows assessment of a wide spectrum of metabolites, including fatty acids, carbohydrates, and amino acids, that are closely involved in cellular physiology, structure, signaling, and disease onset. “Hopefully, this will offer better insight into the biological mechanisms of the early stages of metabolic disorders,” he says.  The approach combines two chromatographic techniques (see sidebar, “The Experiment”) to cover as fully as possible the numerous metabolic pathways likely to be affected. Ong explains: “The two techniques offer different capabilities for measuring a wide range of major biomolecules. For example, carbohydrates, amino acids and a large spectrum of fatty acids are detected using GC-MS, whereas many larger, less volatile molecules, such as sphingolipids and a wide range of phospholipids, are measured using LC-MS.”  

Fig 1: Base peak MS chromatograms of control, pre-diabetic, and diabetic samples indicate few defining differences.
Fig 2: Multivariate analysis Fig 2: Multivariate analysis (OPLS-DA) shows that the three cohorts separate into distinct clusters. Green: Control; Blue; Pre-diabetic; Red: Diabetic

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. theanalyticalscientist.com/issues/0613/201
  2. F. Xu et al., “Metabolic Signature Shift in Type 2 Diabetes Mellitus Revealed by Mass Spectrometry-based Metabolomics,” J. Clin. Endocrinol. Metab 98 (6) E1060-E1065 (2013).

About the Author(s)

Rich Whitworth

Rich Whitworth completed his studies in medical biochemistry at the University of Leicester, UK, in 1998. To cut a long story short, he escaped to Tokyo to spend five years working for the largest English language publisher in Japan. "Carving out a career in the megalopolis that is Tokyo changed my outlook forever. When seeing life through such a kaleidoscopic lens, it's hard not to get truly caught up in the moment." On returning to the UK, after a few false starts with grey, corporate publishers, Rich was snapped up by Texere Publishing, where he spearheaded the editorial development of The Analytical Scientist. "I feel honored to be part of the close-knit team that forged The Analytical Scientist – we've created a very fresh and forward-thinking publication." Rich is now also Content Director of Texere Publishing, the company behind The Analytical Scientist.

More Articles by Rich Whitworth

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.